Before co-founding Vie Ventures, from 2019-2025, he was Managing Director of The T1D Fund: A Breakthrough T1D Venture, the first and largest T1D-focused impact investing fund established to drive investments toward cures for type 1 diabetes through equity investments.
From 2012 until 2019, Steven was the Founder, President and Chief Executive Officer of Aratana Therapeutics, Inc. (NASDAQ: PETX) focused on the licensing, development and commercialization of innovative pet therapeutics.
He was previously a Managing Director at MPM Capital where his investment scope included both venture and buyout transactions across the pharmaceutical and medical technology industries. His investment experience also includes positions at The Carlyle Group, Apax Partners and 1315 Capital. Over the past decades, he has founded, invested in, and/or been involved with several life sciences companies including Align Technologies, MedPointe, ESP Pharma, SkinMedica, Omrix, Pharmathene, Xanodyne, Syndax, EKR Therapeutics, Proteon, Rhythm, and many others.
Previously, Steven was Assistant Clinical Professor of Medicine at Columbia University. He received a Doctor of Medicine degree from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. Steven holds an MBA in Finance from the Wharton School of the University of Pennsylvania and a BA in Chemistry from the University of Kansas.
Managing Director
2004-2012
Managing Director
2019-2025
on LinkedIn
245 Main St, Floor 2,
Cambridge, MA 02142
© 2025 Vie Ventures Inc.